TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04390763
Drug: nab-paclitaxel
Normalized name: NAB-PACLITAXEL COMPONENT PACLITAXEL
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: SOC chemotherapy
Study: NCT03432884
Drug: BGB-3111
Normalized name: BGB-DXP593
DrugBank: BGB-DXP593 (DB16357)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive BGB-3111
Study: NCT03432884
Drug: Moxifloxacin
Normalized name: Moxifloxacin
DrugBank: Moxifloxacin (DB00218)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subjects will receive Moxifloxicin
Study: NCT03802565
Drug: Tolperisone
Normalized name: tolperisone
DrugBank: Tolperisone (DB06264)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TID
Study: NCT00876226
Drug: Citalopram
Normalized name: Citalopram
DrugBank: Citalopram (DB00215)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Citalopram pharmacokinetics will be studies in subjects with short bowel syndrome.~Citalopram 20mg orally will be given to the subjects and on the seventh day blood will be drawn at hours 0,1,2,3,4,6,8,12,16 and 24 hours post-dose.
Study: NCT01616849
Drug: cisplatin and 5-Fu combined with nimotuzumab
Normalized name: 5-FU
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: DDP+5-Fu DDP 100 mg/m2 intravenous infusion in day1, 5-Fu 1000mg/m2/d continuous intravenous infusion on days 1 through 4, both drugs are given every 3 weeks.~Nimotuzumab 200mg/d, intravenous infusion every week
Study: NCT03430661
Drug: ACT-246475
Normalized name: ACT-246475
DrugBank: Selatogrel (DB15163)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lyophilized ACT-246475A to be reconstituted with 1 mL of water for injection
Study: NCT03430661
Drug: Clopidogrel
Normalized name: Clopidogrel
DrugBank: Clopidogrel (DB00758)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Tablet for oral administration (300 or 600 mg)
Study: NCT03430661
Drug: Prasugrel
Normalized name: Prasugrel
DrugBank: Prasugrel (DB06209)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Tablet for oral administration (60 mg)
Study: NCT03430661
Drug: Ticagrelor
Normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tablet for oral administration (180 mg)
Study: NCT00055861
Drug: docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT00672841
Drug: Preemptive Therapy with Anidulafungin
Normalized name: Anidulafungin
DrugBank: Anidulafungin (DB00362)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Subjects in the active surveillance arm who develop a single positive β-D-glucan test will receive preemptive anidulafungin intravenously. Preemptive therapy will include a loading dose of 200mg followed by 100mg maintenance therapy once a day. The loading and maintenance doses are derived from the FDA cleared schedule for Invasive Candidiasis and candidemia. Preemptive therapy will continue for 14 days.
Study: NCT02124759
Drug: Sevelamer
Normalized name: Sevelamer
DrugBank: Sevelamer (DB00658)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1.6 g sevelamer + 4.4 g maltodextrin three times a day
Study: NCT02124759
Drug: Synbiotic
Normalized name: Synotic
DrugBank: Fluocinolone acetonide (DB00591)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5 g of oligofructose + 1 g Bifidobacterium longum R0175 (4 billion colony forming units (CFU)/g) three times a day.
Study: NCT01364597
Drug: Brivaracetam (BRV)
DrugBank: Brivaracetam (DB05541)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: The max BRV dose will be 5.0 mg/kg/day, not to exceed a dose of 200 mg/day for subjects with body weight \>40kg. Subjects may receive oral solution or oral tablets. The LTFU subjects will start dosing in N01266 on the individualized BRV dose they were receiving at the completion of the core study. Subjects must be able to tolerate the min BRV dose specified in the core study to be eligible for entry into the Evaluation Period of N01266. Dose can be adjusted as considered necessary by the Investigator and required by the subject's medical condition. All subjects who prematurely discontinue the study should complete an EDV and have their BRV dose down titrated by a maximum of half the dose every week for a maximum of 4 weeks until a dose of 1 mg/kg/day (50 mg/day for subjects with body weights \>50kg) is reached.
Study: NCT02124759
Drug: Maltodextrin
Normalized name: Maltodextrin
DrugBank: Maltodextrin (DB12583)
Approvals — FDA: no, EMA: no, PMDA: no
Description: This is a control group. Maltodextrin, 6 g three times a day
Study: NCT00565669
Drug: Cyclosporin A Restasis®
DrugBank: Cyclo(his-pro) (DB02414)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00565669
Drug: Blink tears
Normalized name: Blink Tears
DrugBank: Polyethylene glycol 400 (DB11077)
Approvals — FDA: no, EMA: no, PMDA: no
Description: blink tears to be used twice a day
Study: NCT00565669
Drug: Systane
Normalized name: Systane
DrugBank: Propylene glycol (DB01839)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: systane to be used twice a day
Study: NCT01060605
Drug: rapamycin
Normalized name: Rapamycin
DrugBank: Sirolimus (DB00877)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Pre-transplant rapamycin is administered for at least four weeks prior to the first islet infusion at the dose of 0.1 mg/kg (target trough levels: 8-10 ng/mL).
Study: NCT02624388
Drug: Genistein
Normalized name: Genistein
DrugBank: Genistein (DB01645)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estrogen-like compound (isoflavone) derived from soybeans
Study: NCT01987232
Drug: Carfilzomib
Normalized name: Carfilzomib
DrugBank: Carfilzomib (DB08889)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Administered by intravenous infusion.
Study: NCT01987232
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Administered by intravenous infusion.
Study: NCT01987232
Drug: Etoposide
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Administered by intravenous infusion.
Study: NCT01451632
Drug: MM-121
Normalized name: 2X-121
DrugBank: 2X-121 (DB16063)
Approvals — FDA: no, EMA: no, PMDA: no
Description: escalating doses MM-121 IV QW
Study: NCT01451632
Drug: Irinotecan
Normalized name: Irinotecan
DrugBank: Irinotecan (DB00762)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 180 mg/m2 IV Q2W
Study: NCT01451632
Drug: Cetuximab
Normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: escalating doses cetuximab IV QW
Study: NCT01718145
Drug: Daclatasvir
Normalized name: Daclatasvir
DrugBank: Daclatasvir (DB09102)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT01718145
Drug: Asunaprevir
Normalized name: asunaprevir
DrugBank: Asunaprevir (DB11586)
Approvals — FDA: no, EMA: no, PMDA: yes
Study: NCT01718145
Drug: Ribavirin
Normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01718145
Drug: Telaprevir
Normalized name: Telaprevir
DrugBank: Telaprevir (DB05521)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT04089345
Drug: Ustekinumab
Normalized name: Ustekinumab
DrugBank: Ustekinumab (DB05679)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: All patients will receive intravenously (IV) ustekinumab \~6mg/kg at baseline and subcutaneously (SC) ustekinumab 90mg every 8 weeks thereafter until Week 48.
Study: NCT00637806
Drug: Megestrol acetate concentrated suspension 110 mg/mL
DrugBank: Megestrol acetate (DB00351)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Megestrol acetate concentrated suspension 110 mg/mL given as an oral dose of 550 mg (5 mL) once per day for 56 days, with an optional 28 days extension phase
Study: NCT00637806
Drug: Megestrol acetate concentrated suspension 60 mg/mL
DrugBank: Megestrol acetate (DB00351)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Megestrol acetate concentrated suspension 60 mg/mL given as an oral dose of 300 mg (5 mL) once per day for 56 days, with an optional 28 days extension phase
Study: NCT00561470
Drug: Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®)
Normalized name: Aflibercept
DrugBank: Aflibercept (DB08885)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 4 mg/kg of Aflibercept was administered IV over 1 hour on Day 1, every 2 weeks.
Study: NCT00568087
Drug: N-acetylcysteine
Normalized name: N-acetylcysteine
DrugBank: Acetylcysteine (DB06151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will take oral N-acetylcysteine 900 mg/day for 1 week, 1800 mg/day for 1 week, 2700 mg/day for 1 week, and then 3600 mg/day.
Study: NCT00426777
Drug: risedronate
Normalized name: Risedronate
DrugBank: Risedronic acid (DB00884)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: risedronate 35mg tablet, weekly for 12 months
Study: NCT00426777
Drug: risedronate
Normalized name: Risedronate
DrugBank: Risedronic acid (DB00884)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 35mg weekly
Study: NCT00426777
Drug: Control
Normalized name: Control
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: risedronate-matched placebo weekly
Study: NCT00009191
Drug: Sertraline [Zoloft]
DrugBank: Sertraline (DB01104)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01100892
Drug: Once-daily insulin detemir
Normalized name: Insulin Detemir
DrugBank: Insulin detemir (DB01307)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Insulin detemir is a long-acting insulin analog. Starting dose 0.1 units/kg/day (titrated according to the results of home blood glucose monitoring).
Study: NCT01307306
Drug: Humulin R
Normalized name: HumuLIN R
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Humulin R (U-100) will be given i.v. The dose given will be adjusted in order to achieve a blood glucose level of 130-140 mg/dl.
Study: NCT01072448
Drug: Indacaterol 75 μg
Normalized name: indacaterol
DrugBank: Indacaterol (DB05039)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Indacaterol was supplied in powder filled capsules together with a single-dose dry-powder inhaler (SDDPI) device.
Study: NCT02222441
Drug: Palbociclib alone
Normalized name: Palbociclib
DrugBank: Palbociclib (DB09073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: A single 125 mg dose of palbociclib free base capsule given orally alone in the fed state, followed by 120 hours of PK sample collection.
Study: NCT02222441
Drug: Palbociclib plus Modafinil
Normalized name: Palbociclib
DrugBank: Modafinil (DB00745)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: For Cohort 1, modafinil 200 mg once daily for 7 days, followed by 400 mg once daily for 25 days; on Day 28, a single oral 125 mg dose of palbociclib will be given with modafinil after a meal, followed by 120 hours of PK sample collection.
Study: NCT02222441
Drug: Palbociclib plus pioglitazone
Normalized name: Palbociclib
DrugBank: Pioglitazone (DB01132)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: For Cohort 2, pioglitazone 45 mg once daily for a total of 19 days; On Day 15, a single oral 125 mg dose of palbociclib will be given with pioglitazone after a meal, followed by 120 hours of PK sample collection.
Study: NCT01307306
Drug: Metformin
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Metformin 850 mg q. 8 hours will be given to decrease blood glucose to 130-140 mg/dl.
Study: NCT01072448
Drug: Placebo to indacaterol
DrugBank: Indacaterol (DB05039)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Placebo to indacaterol was supplied in powder filled capsules together with a single-dose dry-powder inhaler (SDDPI) device.
Study: NCT02918552
Drug: sodium nitrite
Normalized name: Sodium Nitrite
DrugBank: Nitrous acid (DB09112)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subjects to receive active study drug three times daily during treatment period and then post treatment testing period.
Study: NCT02918552
Drug: Control
Normalized name: Control
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subjects randomized to placebo to receive three times daily during treatment period and then post treatment testing period.
Study: NCT03652116
Drug: Wound infiltration by Bupivacaine
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subcutaneous and subrectal infiltration with 0.25 % Bupivacaine diluted in 20 ml normal saline before closure of the wound
Study: NCT04262765
Drug: Ramipril, Amlodipine and Atorvastatin
DrugBank: Ramipril (DB00178)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: compare the pharmacokinetic of ramipril (and ramiprilat), atorvastatin as atorvastatin calcium trihydrate, amlodipine as amlodipine besilate from reference products given as a multiple dose
Study: NCT03485911
Drug: BCX7353 capsules
Normalized name: BCX7353
DrugBank: Berotralstat (DB15982)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: BCX7353 oral capsules administered once daily
Study: NCT02392507
Drug: Necitumumab
Normalized name: Necitumumab
DrugBank: Necitumumab (DB09559)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Administered IV
Study: NCT02392507
Drug: Nab-Paclitaxel
Normalized name: NAB-PACLITAXEL COMPONENT PACLITAXEL
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Administered IV
Study: NCT02392507
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Administered IV
Study: NCT01802333
Drug: Cytarabine
Normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT01802333
Drug: Daunorubicin Hydrochloride
Normalized name: Daunorubicin Hydrochloride
DrugBank: Daunorubicin (DB00694)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT01802333
Drug: Idarubicin
Normalized name: Idarubicin
DrugBank: Idarubicin (DB01177)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT01802333
Drug: Vorinostat
Normalized name: Vorinostat
DrugBank: Vorinostat (DB02546)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT06339554
Drug: Alectinib 150 MG [Alecensa]
Normalized name: alectinib 150 MG [Alecensa]
DrugBank: Alectinib (DB11363)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: First line treatment for cohorts A and B
Study: NCT01205074
Drug: Non selective beta blocker - Propranolol
Normalized name: beta-Propranolol
DrugBank: Propranolol (DB00571)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00517985
Drug: Duloxetine
Normalized name: Duloxetine
DrugBank: Duloxetine (DB00476)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: During the current study, for a short period of time participants will receive a placebo (a pill that looks like the study drug but which does not contain any medication), although during the majority of the study, participants will be receiving the actual study medication (Duloxetine). The initial dose of Duloxetine to be given will be a 30 mg dose with the dosage increased over time to 60 mg per day. This study will be blinded, meaning that participants will not know whether they are taking placebo or the study drug. However, all subjects will receive duloxetine for the majority of the time they are enrolled in the trial. Investigators will know when subjects are receiving the placebo but in order to maintain the blinding of this study, the study staff will not be able to tell participants when they are taking placebo and when they are taking Duloxetine.
Study: NCT01819857
Drug: Zofran 8 mg
Normalized name: Zofran 8 MG Oral Tablet
DrugBank: Ondansetron (DB00904)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: intravenous administration of 8 mg ondansetron
Study: NCT01437540
Drug: Aclidinium Bromide/Formoterol Fumarate
Normalized name: Aclidinium Bromide/Formoterol Fumarate 400 MCG/1 ACTUATION-12 MCG/1 ACTUATION Inhalation Aerosol Powder
DrugBank: Clidinium (DB00771)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Inhaled aclidinium bromide 400 μg/formoterol fumarate 12 μg, high dose twice per day
Study: NCT01437540
Drug: Formoterol Fumarate
Normalized name: Formoterol Fumarate
DrugBank: Formoterol (DB00983)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Inhaled formoterol fumarate 12 μg, twice per day
Study: NCT04148885
Drug: nab-paclitaxel
Normalized name: NAB-PACLITAXEL COMPONENT PACLITAXEL
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Patients firstly receive nab-paclitaxel 100 mg/m\^2 (iv, 30 minutes) on days 1, 8, and 15 for 3 weeks, followed by one week without treatment. Treatment repeats every 4 weeks for up to 6 circles in the absence of disease recurrence or unacceptable toxicity.
Study: NCT04148885
Drug: carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Patients secondly receive carboplatin AUC=5 (iv, 30 minutes) on days 1 for 3 weeks, followed by one week without treatment. Treatment repeats every 4 weeks for up to 6 circles in the absence of disease recurrence or unacceptable toxicity.
Study: NCT02558543
Drug: Stromal Vascular fraction
Normalized name: Autologous stromal vascular fraction from adipose tissue
DrugBank: Autologous adipose-derived stromal vascular fraction cells (DB18679)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00002615
Drug: cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00002615
Drug: epirubicin hydrochloride
Normalized name: Epirubicin Hydrochloride
DrugBank: Epirubicin (DB00445)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01319851
Drug: Alefacept
Normalized name: Alefacept
DrugBank: Alefacept (DB00092)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.25 mg/kg IV on day -40 and day -39 0.5 mg/kg IV on days -33, -26, -19 and -12 Alefacept was diluted in sterile water (2 ml total volume) and administered via i.v. push followed by a normal saline flush per package insert.
Study: NCT04492072
Drug: Oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intervention
Study: NCT01097252
Drug: weekly cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: weekly cisplatin 40mg/m2, 6 cycles
Study: NCT04492072
Drug: Misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Control
Study: NCT05621005
Drug: Rifaximin 550 milligram Oral Tablet [XIFAXAN]
DrugBank: Rifaximin (DB01220)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rifaximin was given on dose of 550 milligram every 12 hours orally for at least 3 months
Study: NCT01097252
Drug: tri-weekly cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: cisplatin 75mg/m2, 3cycles, every 3 weeks
Study: NCT00100841
Drug: oxaliplatin
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT02920177
Drug: platelet-rich plasma injection
Normalized name: plasma protein fraction Injection
DrugBank: Platelet Rich Plasma (DB19295)
Approvals — FDA: no, EMA: no, PMDA: no
Description: platelet-rich plasma injection
Study: NCT03798600
Drug: Caspofungin
Normalized name: Caspofungin
DrugBank: Caspofungin (DB00520)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: In accordance with routine clinical practice, Caspofungin will be given at the loading dose of 70 mg followed by 50 mg daily (for people \< 80 kg body weight). No dose reduction will be performed in Child-Pugh score A or B. Duration of therapy will be performed in accordance with ESCMID guidelines and clinical conditions.
Study: NCT00003340
Drug: topotecan hydrochloride
Normalized name: Topotecan Hydrochloride
DrugBank: Topotecan (DB01030)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03080766
Drug: Decitabine
Normalized name: Decitabine
DrugBank: Decitabine (DB01262)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Decitabine (trade name Dacogen®) is a cytidine deoxynucleoside analogue, which selectively inhibits DNA methyltransferases at low doses, resulting in gene promoter hypomethylation that can result in reactivation of tumor suppressor genes, induction of cellular differentiation or cellular senescence followed by programmed cell death.
Study: NCT00419172
Drug: Deferasirox
Normalized name: Deferasirox
DrugBank: Deferasirox (DB01609)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT00419172
Drug: Rifampicin
Normalized name: Rifampicin
DrugBank: Rifampin (DB01045)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02192775
Drug: MV-NIS
Normalized name: Toto ni vavalagi oil
DrugBank: Castor oil (DB11113)
Approvals — FDA: no, EMA: no, PMDA: no
Description: one dose in conjunction with a 4 day course intravenously
Study: NCT04527211
Drug: Ivermectin
Normalized name: Ivermectin
DrugBank: Ivermectin (DB00602)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of ivermectin 200 mcg/kg every week for seven weeks
Study: NCT01478074
Drug: G-CSF
Normalized name: G-CSF
DrugBank: Filgrastim (DB00099)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 5 mcg/kg daily from day -7 until post-nadir ANC \> 1000
Study: NCT01478074
Drug: Cytarabine
Normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 2 g/m2 daily from day -6 through -2
Study: NCT01478074
Drug: Fludarabine
Normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg/m2 daily from day -6 through -2
Study: NCT02134353
Drug: Inhaled mannitol
Normalized name: mannitol Inhalant Product
DrugBank: Mannitol (DB00742)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Inhaled mannitol 400 mg BD for 26 weeks
Study: NCT04101929
Drug: Apatinib
Normalized name: Apatinib
DrugBank: Rivoceranib (DB14765)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients receive Apatinib 250mg po qd , Treatment repeats every 4 weeks until the disease recurrence or unacceptable toxicity，death or begin a novel therapeutic.
Study: NCT04101929
Drug: S-1 capsule
DrugBank: Tegafur (DB09256)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Patients receive S-1 capsule According to the body surface area \<1.25m2 60mg/d, 1.25 \~ 1.5 m2 80 mg/d, \> 1.5m2 100mg/d po bid, taking 7 days, stopping for 7 days, 28 days for 1 cycle, Treatment repeats until the disease recurrence or unacceptable toxicity，death or begin a novel therapeutic.
Study: NCT04101929
Drug: Irinotecan
Normalized name: Irinotecan
DrugBank: Irinotecan (DB00762)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Patients receive Irinotecan According to the body surface area of 180 mg/m2, ivgg/90min, once every two weeks. Continuous chemotherapy until the criteria for discontinuation of the drug are met (eg, progression of the disease, intolerance of adverse reactions, or withdrawal of informed consent by the patient).~Because the toxicity of apatinib or irinotecan or tigeol in the chemotherapy regimen meets the withdrawal criteria, the drug can be discontinued alone and the exact duration of the trial treatment recorded.
Study: NCT03164655
Drug: Oxaliplatin, Cetuximab, Bevacizumab, Panitumumab, Irinotecan, Leucovorin, 5-Fluorouracil
DrugBank: Cetuximab (DB00002)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Oxaliplatin 100 mg/m² infusion in 2 hours, Cetuximab 500mg/m² infusion in 2 hours, Bevacizumab 5 mg/kg infusion in 30 minutes, Panitumumab 6 mg/kg, Irinotecan 180 mg/m² over 90 minutes to begin 30 minutes after folinic acid infusion is started, Leucovorin 400 mg/m² infusion in 2 hours, 5-Fluorouracil 2400 mg/m² infusion continuous in 46h
Study: NCT00358956
Drug: ZD6474 (vandetanib)
Normalized name: Vandetanib
DrugBank: Vandetanib (DB05294)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 100 mg once daily oral tablet